Table of Contents
Advances in Vascular Medicine
Volume 2014 (2014), Article ID 542034, 4 pages
http://dx.doi.org/10.1155/2014/542034
Research Article

The Impact of Warfarin on Patients with End Stage Renal Disease

1Department of Surgery, Medical College of Wisconsin, Milwaukee, WI 53226, USA
2Department of Vascular Surgery, Southern Illinois University, Springfield, IL 62901, USA
3Department of Anesthesiology, Medical College of Wisconsin, Milwaukee, WI 53226, USA

Received 16 July 2014; Revised 17 August 2014; Accepted 28 August 2014; Published 8 September 2014

Academic Editor: Arnon Blum

Copyright © 2014 Anahita Dua et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Introduction. A deficiency in vitamin K through the utilization of warfarin may result in increased vascular calcification and complications. This study aimed to determine the impact of warfarin administration on patients with end stage renal disease (ESRD) in a large, national sample. Methods. A retrospective analysis using the 2005–2010 National Inpatient Sample (NIS), a part of the Health Care Utilization Project (HCUP), was completed using ICD-9 diagnosis codes to capture patients with ESRD prescribed and not prescribed warfarin. Statistical analysis was through ANOVA and chi-squared testing. Results. From 2005–2010, 927,814 patients with ESRD were identified nationally. 3.5% (32,737) were prescribed warfarin. Patients prescribed warfarin had an average age of 64 years and 51% were male. For every comorbid condition (amputation, congestive heart failure, chronic obstructive pulmonary disorder, cerebrovascular accident, diabetes, hypertension, myocardial infarction, peripheral vascular diasese, and valvular disease) patients prescribed Warfarin had significantly higher rates of disease as compared to their nonwarfarin ESRD counterparts. ESRD patients prescribed warfarin had significantly shorter length of stay but increased hospital charges. They were more likely to be discharged to home and had significantly decreased in-hospital mortality. Conclusion. Patients with ESRD taking warfarin are more likely to have comorbidities and/or complications but have a decreased LOS and in-hospital mortality compared to their ESRD counterparts not administered warfarin.